Recent discussions on X about iRhythm Technologies (IRTC) have been sparked by a mix of bullish and bearish perspectives following a critical report from an investment firm. Posts on the platform highlight a 'Strong Sell' opinion from a notable research entity, suggesting significant downside risk due to regulatory and competitive concerns. The intensity of these debates reflects a divided community, with some users pointing to potential long-term challenges for the stock.
On the flip side, there are voices on X expressing optimism, particularly citing a new Buy rating from a major financial institution with a price target well above the current trading level. This positive sentiment is further fueled by recent news of strong clinical study results for the company’s cardiac monitoring technology. The contrasting views make IRTC a focal point of heated discussion among investors on the platform.
Note: This discussion summary was generated from an AI condensation of post data.
iRhythm Technologies Insider Trading Activity
iRhythm Technologies insiders have traded $IRTC stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $IRTC stock by insiders over the last 6 months:
- QUENTIN S. BLACKFORD (President and CEO) has made 0 purchases and 8 sales selling 52,252 shares for an estimated $7,311,308.
- CHAD PATTERSON (Chief Commercial Officer) has made 0 purchases and 8 sales selling 28,761 shares for an estimated $3,610,055.
- PATRICK MICHAEL MURPHY (CBO and CLO) has made 0 purchases and 2 sales selling 16,330 shares for an estimated $1,791,041.
- SUMI SHRISHRIMAL (EVP, Chief Risk Officer) has made 0 purchases and 2 sales selling 8,595 shares for an estimated $999,665.
- MINANG TURAKHIA (EVP, CMO & CSO) has made 0 purchases and 2 sales selling 8,434 shares for an estimated $992,962.
- DANIEL G. WILSON (Chief Financial Officer) has made 0 purchases and 3 sales selling 7,512 shares for an estimated $981,670.
- ABHIJIT Y TALWALKAR has made 0 purchases and 2 sales selling 5,312 shares for an estimated $839,380.
- MERVIN SMITH (EVP Strategic Business Ops) sold 616 shares for an estimated $101,245
- MARC WADE ROSENBAUM (Chief Accounting Officer) sold 226 shares for an estimated $35,918
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
iRhythm Technologies Hedge Fund Activity
We have seen 170 institutional investors add shares of iRhythm Technologies stock to their portfolio, and 133 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 695,758 shares (-31.6%) from their portfolio in Q2 2025, for an estimated $107,118,901
- MACKENZIE FINANCIAL CORP removed 426,141 shares (-36.9%) from their portfolio in Q2 2025, for an estimated $65,608,668
- SLATE PATH CAPITAL LP removed 365,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $56,256,984
- ALYESKA INVESTMENT GROUP, L.P. removed 351,745 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $36,820,666
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 326,508 shares (-52.9%) from their portfolio in Q2 2025, for an estimated $50,269,171
- HOLOCENE ADVISORS, LP added 298,347 shares (+2023.1%) to their portfolio in Q2 2025, for an estimated $45,933,504
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 295,432 shares (-32.7%) from their portfolio in Q2 2025, for an estimated $45,484,710
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
iRhythm Technologies Analyst Ratings
Wall Street analysts have issued reports on $IRTC in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 08/21/2025
- Needham issued a "Buy" rating on 08/01/2025
- Wells Fargo issued a "Overweight" rating on 08/01/2025
- Canaccord Genuity issued a "Buy" rating on 08/01/2025
- JP Morgan issued a "Overweight" rating on 08/01/2025
- Morgan Stanley issued a "Overweight" rating on 07/15/2025
- Baird issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for iRhythm Technologies, check out Quiver Quantitative's $IRTC forecast page.
iRhythm Technologies Price Targets
Multiple analysts have issued price targets for $IRTC recently. We have seen 8 analysts offer price targets for $IRTC in the last 6 months, with a median target of $180.0.
Here are some recent targets:
- Joanne Wuensch from Citigroup set a target price of $183.0 on 08/21/2025
- An analyst from B of A Securities set a target price of $200.0 on 08/20/2025
- William Plovanic from Canaccord Genuity set a target price of $170.0 on 08/01/2025
- David Saxon from Needham set a target price of $180.0 on 08/01/2025
- Nathan Treybeck from Wells Fargo set a target price of $180.0 on 08/01/2025
- Allen Gong from JP Morgan set a target price of $190.0 on 08/01/2025
- Cecilia Furlong from Morgan Stanley set a target price of $147.0 on 07/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
